ELISA法检测艾滋病保护性抗体

一种新型检测方法能够在HIV阳性血清患者中检测R7V抗体，从而可以帮助医生鉴别那些非进展性患者。

HIV患者R7V抗体阳性能够中和所有HIV病毒株，而无论病毒的基因型、患者的地理区域，甚至那些抗逆转录药物抵抗的病毒株。当HIV患者被检测出血清阳性后10年仍然无症状的时候，这些患者被认为是非进展者。这些患者CD4计数保持稳定，病毒负荷不会升高。

这种新型检测方法是酶联免疫吸附法(ELISA)。抗逆转录治疗的疗效并不会降低，但是抗病毒药物能够增加患者的副作用以及不方便。这项检测能够帮助医生作出治疗决定，能够用于在开始的时候血清阳性的非进展者。与CD4计数和病毒负荷联合应用，有助于医生决定开始或者不开始治疗。

对989例HIV阳性患者收集的血清进行回顾性检测分析，证实在HIV阳性患者中出现R7V抗体与非进展性之间的相关性为85.7%。该检测已经由Ivagen(Nimes, France)从芝加哥大学Jean Claude Chermann教授获得了许可证。

ELISA for AIDS-Protective Antibodies
 
A new test detects the presence of anti-R7V antibodies in HIV-seropositive patients, which helps doctors to identify patients who may be nonprogressors.

Anti-R7V antibodies from HIV-positive patients have the property of neutralizing all strains of HIV, no matter the genotype, phenotype, or geographical area of the patient, even if the strain is resistant to anti-retroviral drugs. When HIV patients remain asymptomatic for more than 10 years after being detected as seropositive, they are considered as being nonprogressors. They have stable CD4 counts and viral load that does not evolve.

The new test is an enzyme-linked immunosorbent assay (ELISA). It does not discount the efficacy of anti-retroviral therapy, but the use of anti-viral agents can cause side effects and inconveniences for patients. The test helps doctors make therapeutic decisions and is used at the initiation of seropositivity to detect nonprogressors. In conjunction with CD4 counts and viral load, it helps doctors decide whether or not to apply therapy.

A retrospective study of 989 samples collected from HIV-positive patients demonstrated a correlation of 85.7% between nonprogression and the presence of anti-R7V antibodies in HIV-positive patients. The test has been licensed from Professor Jean Claude Chermann of the University of Chicago (IL, USA) by Ivagen (Nimes, France).